These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 16021173)

  • 1. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis.
    Chapman MS; Schachner LA; Breneman D; Boguniewicz M; Gold MH; Shull T; Linowski GJ; Jaracz E;
    J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 2):S177-85. PubMed ID: 16021173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study.
    Schachner LA; Lamerson C; Sheehan MP; Boguniewicz M; Mosser J; Raimer S; Shull T; Jaracz E;
    Pediatrics; 2005 Sep; 116(3):e334-42. PubMed ID: 16140675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tacrolimus ointment in pediatric Patients with moderate to severe atopic dermatitis.
    Singalavanija S; Noppakun N; Limpongsanuruk W; Wisuthsarewong W; Aunhachoke K; Chunharas A; Wananukul S; Akaraphanth R
    J Med Assoc Thai; 2006 Nov; 89(11):1915-22. PubMed ID: 17205874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies.
    Paller AS; Lebwohl M; Fleischer AB; Antaya R; Langley RG; Kirsner RS; Blum RR; Rico MJ; Jaracz E; Crowe A; Linowski GJ;
    J Am Acad Dermatol; 2005 May; 52(5):810-22. PubMed ID: 15858471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.
    Reitamo S; Harper J; Bos JD; Cambazard F; Bruijnzeel-Koomen C; Valk P; Smith C; Moss C; Dobozy A; Palatsi R;
    Br J Dermatol; 2004 Mar; 150(3):554-62. PubMed ID: 15030341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients.
    Koo JY; Fleischer AB; Abramovits W; Pariser DM; McCall CO; Horn TD; Gottlieb AB; Jaracz E; Rico MJ
    J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 2):S195-205. PubMed ID: 16021175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial.
    Doss N; Reitamo S; Dubertret L; Fekete GL; Kamoun MR; Lahfa M; Ortonne JP
    Br J Dermatol; 2009 Aug; 161(2):427-34. PubMed ID: 19416227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis.
    Reitamo S; Ortonne JP; Sand C; Cambazard F; Bieber T; Fölster-Holst R; Vena G; Bos JD; Fabbri P; Groenhoej Larsen C;
    Br J Dermatol; 2005 Jun; 152(6):1282-9. PubMed ID: 15948994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use.
    Paller AS; Eichenfield LF; Kirsner RS; Shull T; Jaracz E; Simpson EL;
    Pediatrics; 2008 Dec; 122(6):e1210-8. PubMed ID: 19015204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment.
    Doss N; Kamoun MR; Dubertret L; Cambazard F; Remitz A; Lahfa M; de Prost Y
    Pediatr Allergy Immunol; 2010 Mar; 21(2 Pt 1):321-9. PubMed ID: 19563466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.
    Chen SL; Yan J; Wang FS
    J Dermatolog Treat; 2010 May; 21(3):144-56. PubMed ID: 20394490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis.
    Hanifin JM; Paller AS; Eichenfield L; Clark RA; Korman N; Weinstein G; Caro I; Jaracz E; Rico MJ;
    J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 2):S186-94. PubMed ID: 16021174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study.
    Pacor ML; Di Lorenzo G; Martinelli N; Mansueto P; Rini GB; Corrocher R
    Clin Exp Allergy; 2004 Apr; 34(4):639-45. PubMed ID: 15080819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis.
    Fleischer AB; Abramovits W; Breneman D; Jaracz E;
    J Dermatolog Treat; 2007; 18(3):151-7. PubMed ID: 17538803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children.
    Remitz A; Harper J; Rustin M; Goldschmidt WF; Palatsi R; van der Valk PG; Sharpe G; Smith CH; Dobozy A; Turjanmaa K;
    Acta Derm Venereol; 2007; 87(1):54-61. PubMed ID: 17225017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream.
    Abramovits W; Fleischer AB; Jaracz E; Breneman D
    J Drugs Dermatol; 2008 Dec; 7(12):1153-8. PubMed ID: 19137769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle.
    Breneman D; Fleischer AB; Abramovits W; Zeichner J; Gold MH; Kirsner RS; Shull TF; Crowe AW; Jaracz E; Hanifin JM;
    J Am Acad Dermatol; 2008 Jun; 58(6):990-9. PubMed ID: 18359127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
    Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
    Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic CONTROL study.
    Poole CD; Chambers C; Sidhu MK; Currie CJ
    Br J Dermatol; 2009 Dec; 161(6):1335-40. PubMed ID: 19754867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
    Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
    J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.